HEALTH CHAIN GROUP (HCG) acquired by ANJAC BEAUTY & HEALTH
Context
Anjac acquired a majority stake in HCG to accelerate its growth in the nutraceutical space. This is the 17th company to join the Anjac ecosystem. Beyond the acquisition cost, Anjac has committed to a EUR25M investment plan to expand the Velenje production site, aiming to triple its output within 12 months. The historical founders remain as operational partners.
By taking control of Health Chain Group, Anjac Beauty & Health continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Stephid in 2023.
HEALTH CHAIN GROUP (HCG), which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Health Chain Group is a Slovenian specialist in the development and manufacturing of high-end food supplements. The group operates via three key subsidiaries: PharmaLinea (B2B branded ingredients), Hermes Consilium (distribution), and ErgoPharma (manufacturing). HCG is recognized for its scientifically backed formulations and modern Corporate facility located in Velenje, Slovenia.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 01/2026 | YOTTA CAPITAL | VILLARD | FRANCE | Life Sciences | Yotta Capital Partners led a majority buyout of Villard, succeeding the previous sponsorless structure held by CEO. The transaction values the company on a solid growth trajectory, with the management team and historical regional partners reinvesting in the new pool |
| 12/2025 | CHARTERHOUSE | WINBACK | FRANCE | Life Sciences | Charterhouse Capital Partners acquired a majority equity stake in Winback following a competitive process that attracted interest from several top-tier private equity funds. This transaction facilitates the exit of Capza, which had supported the company since late 2021 through a minority "flex equity" structure, and allows the founding duo to cash out a portion of their holdings while reinvesting to remain significant minority shareholders and operational leaders |
| 11/2025 | PFIZER | METSERA | UNITED STATES | Life Sciences | Pfizer has finalized the acquisition of Metsera, an operation designed to fundamentally transform the group’s Internal Medicine portfolio and secure a leading foothold in the obesity treatment sector. The strategic rationale for this transaction centers on a "pipeline-transformation" play, merging the target's highly differentiated clinical-stage obesity candidates with the group's global development and commercial infrastructure |
| 11/2025 | ARLANE | DESSINTEY | FRANCE | Life Sciences | Arlane has acquired a majority stake (approximately two-thirds) in Dessintey through a primary LBO. The transaction allows for the exit of early-stage investors Turenne Sante (via Relyens Innovation Sante) and Credit Agricole Haute-Loire, who invested in 2019 |
| 10/2025 | PUBLIC MARKETS (IPO) | OTTOBOCK | GERMANY | Life Sciences | Ottobock successfully completed its Initial Public Offering on the Frankfurt Stock Exchange, marking the largest German IPO of 2025. The shares were priced at €66.00, with the first trading price reaching €72 |
| 09/2025 | INVESTCorporate | DCC HEALTHCARE | UNITED KINGDOM | Life Sciences | InvestIndustrial finalized the acquisition of DCC Healthcare Limited from the London-listed group DCC plc. This transaction is a strategic corporate carve-out designed to simplify DCC plc's operations, allowing the group to focus resources on its largest and most profitable Energy division |
| 09/2025 | CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENT | PROTEOR | FRANCE | Life Sciences | Proteor has orchestrated a secondary Owner Buy-Out (OBO Bis). The transaction allows Ardian Growth to exit its minority position, which it held since the primary OBO in 2021, realizing a return of approximately 3x money |
| 09/2025 | CAPVEST PARTNERS | STADA | GERMANY | Life Sciences | CapVest Partners agreed to acquire a controlling majority stake in Stada from Bain Capital and Cinven. This deal serves as an alternative to a planned IPO in Frankfurt, which was shelved due to market volatility |
| 08/2025 | TERUMO | ORGANOX | UNITED KINGDOM | Life Sciences | Lauxera Capital Partners has successfully finalized the divestment of its minority equity stake in UK-based OrganOx to Japanese medical giant Terumo, marking the first historical exit for the medtech-focused growth investor |
| 08/2025 | WARBURG PINCUS | SEBIA | FRANCE | Life Sciences | The French medical diagnostics giant Sebia welcomes a new heavyweight investor, Warburg Pincus, into its capital. This transaction, valuing the company at over EUR5 billion, sees the partial exit of minority shareholders CDPQ and ICG |
REFERENCES
Revenue range: 25M - 50M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HEALTH CHAIN GROUP (HCG) by ANJAC BEAUTY & HEALTH are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Target: health chain group (hcg)